Vietnam Investment Review on MSN
Brii Bio presents ENSURE phase 2 data at EASL 2026 supporting BRII 179 for hepatitis B control
DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public ...
DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results